GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crinetics Pharmaceuticals Inc (STU:6Z4) » Definitions » Research & Development

Crinetics Pharmaceuticals (STU:6Z4) Research & Development : €244.07 Mil (TTM As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Crinetics Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Crinetics Pharmaceuticals's Research & Development for the three months ended in Mar. 2025 was €70.52 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was €244.07 Mil.

Crinetics Pharmaceuticals Research & Development Historical Data

The historical data trend for Crinetics Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crinetics Pharmaceuticals Research & Development Chart

Crinetics Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only 46.85 74.57 122.93 154.54 229.35

Crinetics Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.07 54.20 55.78 63.57 70.52

Crinetics Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €244.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crinetics Pharmaceuticals  (STU:6Z4) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Crinetics Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Crinetics Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Crinetics Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crinetics Pharmaceuticals Inc (STU:6Z4) » Definitions » Research & Development
Comparable Companies
MRUS SRRK XENE CPRX VKTX AKRO CRSP PTGX SWTX ACLX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
CRNX:USA
Address
6055 Lusk Boulevard, San Diego, CA, USA, 92121
Website
https://www.crinetics.com
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

Crinetics Pharmaceuticals Headlines

No Headlines